Drugs / sodium stibogluconate
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01009502 | Jul 2009 → Mar 2012 | myelodysplastic syndrome | Northwestern University | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT00498979 | May 2007 → May 2010 | melanoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00629200 | Sep 2006 → Feb 2010 | cancer of unknown primary site | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00311558 | Oct 2005 → May 2011 | cancer | The Cleveland Clinic | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00657618 | Oct 2004 → Apr 2010 | leishmaniasis | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04906031 | Jun 2020 → Feb 2023 | acute myeloid leukemia, myelodysplastic syndrome | First Affiliated Hospital of Jinan University | Unknown | No outcome recorded |
| Phase 2 | NCT01067443 | Mar 2010 → Jun 2011 | visceral leishmaniasis | Drugs for Neglected Diseases | Completed | No outcome recorded |
| Phase 2 | NCT00662012 | Jun 2002 → Oct 2007 | leishmaniasis | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT00508963 | — | cutaneous leishmaniasis, mucocutaneous leishmaniasis | University of California, San Francisco | No longer available | No outcome recorded |
| Comparator or background therapy10 trials | ||||||
| Phase 2 | NCT06798402 Comparator | Feb → Nov 2025 overdue | cutaneous leishmaniasis | Al-Mustafa University College | Recruiting | No outcome recorded |
| Phase 2 | NCT05957978 Comparator | Mar 2024 → Jun 2025 | visceral leishmaniasis | Drugs for Neglected Diseases | Completed | No outcome recorded |
| Phase 2 | NCT00996463 Comparator | Jan → Sep 2010 | — | Waisenmedizin e. V. Promoting Access to Essential Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01011309 Comparator | Oct 2009 → May 2011 | cutaneous leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 2 | NCT00884377 Comparator | Feb 2004 → Jan 2009 | cutaneous leishmaniasis | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 3 | NCT07463040 Comparator | Jan 2027 → Mar 2029 expected | cutaneous leishmaniasis | Institute of Tropical Medicine, Belgium | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05708625 Comparator | Jan 2022 → Dec 2023 | cutaneous leishmaniasis | Zagazig University | Unknown | No outcome recorded |
| Phase 3 | NCT03129646 Comparator | Jan 2018 → Dec 2020 | visceral leishmaniasis | Drugs for Neglected Diseases | Completed | Missed primary |
| Phase 3 | NCT00255567 Comparator | Nov 2004 → Jan 2010 | visceral leishmaniasis | Drugs for Neglected Diseases | Completed | Mixed |
| Phase 4 | NCT01661296 Comparator | Aug 2009 → Aug 2011 | cutaneous leishmaniasis | Sarder Patel Medical College | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-09-30 | Drugs for Neglected Diseases | Results Results of Large-Scale Roll Out of Combination Treatment for Kala-Azar in Eastern Africa Points to Urgency to Treat Disease Victims as Outbreak Surges in South Sudan | DNDi dndi.org ↗
In this large cohort of patients, treated under normal field conditions, the results confirmed the safety and high rate of efficacy of the combination treatment in the fight against this fatal neglected tropical disease. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-09-30 | Drugs for Neglected Diseases | Results of Large-Scale Roll Out of Combination Treatment for Kala-Azar in Eastern Africa Points to Urgency to Treat Disease Victims as Outbreak Surges in South Sudan | DNDi dndi.org ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium stibogluconate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00884377 ↗ |
| Known as | Pentostam | “Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).” NCT00508963 ↗ |
| Known as | SSG | “Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.” PMID 22724029 ↗ Jun 20126“miltefosine, sodium stibogluconate (SSG) or liposomal amphotericin B” PMID 21718522 ↗ Jun 2011 “received intradermal sodium stibogluconate (SSG) (Group I)” PMID 25420793 ↗ Nov 2014 “sodium stibogluconate (SSG)” NCT00311558 ↗ “Sodium Stibogluconate (SSG)” NCT00662012 ↗ “Sodium Stibogluconate (SSG)” NCT07463040 ↗ “Sodium Stibogluconate (SSG)” NCT00657618 ↗ |
| Action | Inhibit | “Define the effectiveness of SSG in inhibiting the protein tyrosine phosphatases src homology proteins (SHP)-1 and SHP-2” NCT00311558 ↗ |
| Route | Intravenous | “SSG IV over 15 minutes” NCT00311558 ↗ |